Add this topic to your myFT Digest for news straight to your inbox
Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing
Doctors hopeful antibody therapy could change treatment for most common type of late-stage breast cancer
UK and Japanese groups’ chemotherapy pact follows $6.9bn alliance on another drug last year
Cancer drug deal will help the pharma group outpace most of its rivals
Pharma companies to share drug development and commercialisation costs as well as profits
Investors call for removal of directors after board rejects highest bid
Businessmen fighting fraud claims vow to stage comeback
Treasury bonds, yen and gold gain ground
Daiichi Sankyo pays Welsh start-up £12.5m for regenerative medicine to fix damaged heart tissue
US regulators have banned imports from 39 laboratories in credibility crisis
Trade in $18bn of Chinese and Indian stockssurge is changes market dynamics
Drugmaker sells its entire 8.9% stake in Sun Pharma
Offloading of India pharma group is good for the Japanese company
Fundamental questions hang over the drugmaker’s business model
Authorities focus on drugs made in four-year-old Mohali plant
International Edition